Atopic Dermatitis

The Atopic Dermatitis pipeline: 107 tracked drugs, 11 approved for this indication.

11 approved / phase 420 Phase 348 Phase 25 Phase 1/219 Phase 14 preclinical / unstaged

Compare the share prices of listed companies in Atopic Dermatitis →

Total attributable cost

$98.8B

$4,979/patient

Drug spend

$23.2B

$1,168/patient

How this is calculated ↗

All severities, self-reported diagnosis (2024 NHIS) · US

The Atopic Dermatitis pipeline

Key trial results for every approved and late-stage drug: Atopic Dermatitis results by drug.

← all assets